Vivos Therapeutics announced that its modified mandibular Repositioning Nighttime Appliance is now eligible for Medicare reimbursement.
Vivos Therapeutics has received acceptance from a Centers for Medicare & Medicaid Services Pricing, Data Analysis and Coding contractor for its modified mandibular Repositioning Nighttime Appliance (mmRNA) device for treating mild to moderate obstructive sleep apnea and snoring in adults.
The mmRNA device has been placed on the PDAC list of oral appliances covered by and billable to Medicare.
Acceptance on the PDAC list marks a step toward increasing commercial insurance coverage to make the mmRNA appliance a more cost-effective solution for non-Medicare beneficiaries.
“This latest regulatory milestone opens the door for Vivos-trained dentists across the country to deliver our life-changing therapeutic technology to the millions of OSA sufferers in the U.S. who are either on Medicare or who have commercial medical insurance coverage that follows Medicare guidelines,” said Kirk Huntsman, Vivos chief executive officer and chairman. “The latest data from our SleepImage home sleep apnea test screening shows that 47% of patients screened were positive for OSA, a far higher prevalence of OSA than has previously been assumed in the industry.”
The mmRNA appliance also allows Vivos-trained dentists to help patients in various clinical applications, such as a standalone therapy for mild and moderate OSA or as an alternative to or an adjunctive therapy with continuous positive airway pressure (CPAP) therapy.